Intalfa 5MIU Injection consists of the active Interferon alfa-2b. It treats various diseases, including cancers and viral infections (chronic hepatitis B, hepatitis C). It is similar to a protein that your body naturally produces called interferon. It modifies the response of the body’s immune system to help fight infections and severe diseases. This medicine helps to suppress viral replication and reduce liver inflammation.

Talk to your doctor if you have any severe heart disease, kidney disorders, liver diseases, history of seizures, autoimmune disorders, thyroid problems, or had an organ transplant before taking Intalfa 5MIU Injection. Administration of this medicine may lead to dental and gum disorders. You should drink extra fluids to help prevent low blood pressure. Patients with a history of autoimmune disorders should be closely monitored for signs and symptoms during treatment.

• Chronic myelogenous leukemia
• Hairy cell leukemia
• Malignant melanoma
• Follicular lymphoma
• Multiple myeloma
• Carcinoid tumor
• Viral infections such as chronic hepatitis B or C)

Intalfa 5MIU Injection works by stimulating the immune system to attack and destroy cancer cells and viruses, and it can also help manage certain symptoms associated with viral infections.

Inform your healthcare provider about all your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Intalfa 5MIU Injection and reduce effectiveness by causing undesirable side effects.

• Store in a refrigerator between 2-8°C (56-46°F).
• It should not be frozen.
• Keep it in its original packaging until it is ready to be used.
• Keep out of the reach of children and pets.

Intalfa 5MIU Injection is typically administered through injection by a healthcare provider. The specific method of administration may vary depending on the condition being treated and the healthcare provider's instructions. If a dose is missed, the patient should contact their healthcare provider for further instructions.

Like all medications, Intalfa 5MIU Injections cause some side effects, although not everyone will experience them. 

Severe:

• Severe depression
• Slow growth in children and adolescents
• Severe allergic reactions
• Chest pain or persistent cough, shortness of breath
• Mental health illness (confusion, hallucinations, changed behavior, trouble concentrating, trouble sleeping)
• Severe stomach pain, black stools, blood in urine or stool
• Eye problems, hearing problems
• Pain, fever
• High sugar levels in the blood

Common:

• Headache, dizziness
• Changes in appetite
• Nausea, vomiting
• Weight loss
• Mood swings
• Joint pain, muscle pain
• Diarrhea, stomach pain
• Thirst, dehydration
• Menstrual problems
• High blood pressure
• Taste change, tooth ache, dry mouth
• Heartburn
• Constipation
• SleepwalkingtoothacHeartburnhe
• Increased sweating, increased need to pass urine
• Bedwetting in children

If you have been prescribed Intalfa 5MIU Injection, it is important to carefully read and understand the warnings and precautions associated with the medication. Patients should be monitored for signs of an allergic reaction, such as rash, itching, or swelling, and should seek immediate medical attention if these symptoms occur. It increases the risk of infection, so patients should avoid close contact with infected persons. Patients with diabetes require close monitoring during treatment. Pregnancy and breastfeeding should be avoided during treatment. Always maintain a healthy and balanced diet to support your overall health and well-being.

1. Merck & Co., Inc., [Revised on Aug 2019] [Accessed on 5th May 2023], https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=50789790-8517-49f9-b97b-8c5ba17b55d2&type=display 
2. R Khanna et al.; Interferon; NCBI Bookshelf; [Revised:2020] [Accessed:5 May 2023], https://www.ncbi.nlm.nih.gov/books/NBK555952/
3. RA Ningrum; Human Interferon Alpha-2b; A therapeutic protein for cancer treatment; [Revised on 2014] [Accessed on 5 May 2023], https://www.ncbi.nlm.nih.gov/books/NBK555952/
4. Merck Sharp & dome BV, Electronic medicines agency (EMA), [Revised on 2010] [Accessed on 5 May 2023], https://www.ema.europa.eu/en/documents/product-information/introna-epar-product-information_en.pdf